Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Transfer of LLPs from Chugai “Our Ticket to Admission” into Pharma Business: Taiyo Pharma COO
November 16, 2017
- FDA Approves Sensor-Embedded Abilify, World’s 1st Digital Pill
November 15, 2017
- Chugai to Offload 13 Off-Patent Brands to Taiyo Holdings
November 15, 2017
- Fujifilm Invests in Tsukuba-Based Upstart, Grabs Transgenic Technologies for iPS Cell Production
November 14, 2017
- Reported Off-Patent Drug Divestment “Not Based on Announcement”: Chugai
November 14, 2017
- Harvoni Drops Out of Top 10 Product List in Japan in June-September: IQVIA
November 13, 2017
- Ethical Drug Sales Up 0.7% in September; 1st DPP-4/SGLT2 Combo Upbeat: Crecon
November 10, 2017
- Takeda’s Relugolix Hits Primary Endpoint in Uterine Fibroids-Tied Pain: Japan PIII
November 10, 2017
- Ono Links Arms with Neurimmune on Neurodegenerative Disease
November 10, 2017
- Gilead’s VP for EMEA Hermans to Replace Orihara as Japan Head
November 10, 2017
- Can Japan’s 1st Enbrel Biosimilar Make Its Mark in RA Follow-On Arena with Self-Injection?
November 10, 2017
- Kyorin Pres. Says AG Strategy Is a “Success,” Nasonex Eyed as 2nd Battlefield
November 9, 2017
- Takata Seiyaku to Take Over MA for MSD’s Gentacin
November 9, 2017
- Mitsubishi Tanabe Grabs Distribution Rights to Clenafin/Jublia in Taiwan
November 9, 2017
- Top Court Dismisses Elplat Patent Infringement Case: Nichi-Iko
November 9, 2017
- Takeda Teams Up with US Medical Device Company to Develop Needle-Free Injection Device Utilizing Pressurized Liquid
November 9, 2017
- Evocalcet Shows Non-Inferiority to Regpara in Japan PIII
November 8, 2017
- Tolvaptan Re-Submitted to US FDA for ADPKD: Otsuka
November 8, 2017
- Santen Will Derive More than 30% of Sales Overseas This Fiscal Year: President
November 8, 2017
- Bayer to Put Digital Technology Proposals to Practical Use; AI-Based Automated Coding Will Reduce Workload by 40%
November 8, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…